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Abstract Adult diffuse low-grade gliomas are slow
growing, World Health Organization grade II lesions with
insidious onset and ultimate anaplastic transformation. The
timing of surgery remains controversial with polarized
practices continuing to govern patient management. As a
result, the management of these patients is variable. The
goal of this questionnaire was to evaluate practice patterns
in Canada. An online invitation for a questionnaire in-
cluding diagnostic, preoperative, perioperative, and post-
operative parameters and three cases with magnetic
resonance imaging data with questions to various treatment
options in these patients was sent to practicing neurosur-
geons and trainees. Survey was sent to 356 email addresses
with 87 (24.7 %) responses collected. The range of years of
practice was less than 10 years 36 % (n = 23),
11–20 years 28 % (n = 18), over 21 years 37 % (n = 24).
Twenty-two neurosurgery students of various years of
training completed the survey. 94 % (n = 47) of surgeons
and trainees (n = 20) believe that we do not know the
‘‘right treatment’’. 90 % of surgeons do not obtain formal
preoperative neurocognitive assessments. 21 % (n = 13)
of surgeons and 23 % of trainees (n = 5) perform a biopsy
upon first presentation. A gross total resection was believed
to increase progression free survival (surgeons: 75 %,
n = 46; trainees: 95 %, n = 21) and to increase overall
survival (surgeons: 64 %, n = 39, trainees: 68 %, n = 15).
Intraoperative MRI was only used by 8 % of surgeons.
Awake craniotomy was the procedure of choice for elo-
quent tumors by 80 % (n = 48) of surgeons and 100 % of
trainees. Of those surgeons who perform awake craniotomy
93 % perform cortical stimulation and 38 % performed
subcortical stimulation. Using the aid of three hypothetical
cases with progressive complexities in tumor eloquence
there was a trend for younger surgeons to operate earlier,
and use awake craniotomy to obtain greater extent of
resection with the aid of cortical stimulation when com-
pared to senior surgeons who still more often preferred a
‘‘wait-and-see’’ approach. Despite the limitations of an
online survey study, it has offered insights into the vari-
ability in surgeon practice patterns in Canada and the need
for a consensus on the workup and surgical management of
this disease.
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Introduction
The management of adult diffuse low-grade gliomas
(LGG) is variable. Mounting non-Class I evidence suggests
that early upfront extensive microsurgical resection of
LGGs is associated with a more favorable prognosis [1–
18]. The level of evidence to support clinical care remains
controversial and we are faced with the ongoing challenge
of designing the best management strategy for individual
patients. Controversies include: the necessary components
of the diagnostic workup; the role of a ‘‘wait-and-see’’
strategy of following patients based on their clinical status
and imaging alone; to the nature and goals of surgical
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intervention; and postoperative management issues
including but not limited to imaging, role of repeat surgery,
adjuvant treatment, and follow-up. The aim of this study is
to gain insight into the practice patterns of neurosurgeons
and trainees in Canada, where the vast majority of neuro-
surgery is centralized and performed at academic centers.
We postulated that when compared to senior neurosur-
geons, trainees and younger neurosurgeons have practice
patterns that (i) utilize more tools in the workup and sur-
gical management of patients (ii) believe that early surgery
can impact outcomes (i.e. overall survival, progression free
survival—PFS etc.) (iii) more readily incorporate awake
craniotomy and mapping for surgical resections.
Methods
A questionnaire was created in English and French on an
online password protected survey system (www.survey
monkey.com). An email with a brief rationale for the study
was sent to practicing neurosurgeons, neurosurgery fellows
and residents across Canada registered at academic centers
or working at hospitals with neurosurgical services. Over
90 % of neurosurgery in Canada is practiced at academic
centers.
The questionnaire asked for symptomatology, preoper-
ative diagnostic tools, wait-and-see strategy versus surgical
treatment, intraoperative applications, and postoperative
management. This was followed by three separate cases of
patients with MRI images demonstrating low-grade lesions
(non-enhancing), and with the question ‘‘How would you
treat this patient?’’. Figure 1 illustrates the flow diagram of
questions. A diffuse LGG was defined in the survey as a
World Health Organization (WHO) grade II entity, with
surgically curative WHO grade I pilocytic astrocytomas
excluded. Pure astrocytic and pure oligodendroglial tumors
were used as examples to determine how histological
subtyping possibly influences treatment decisions.
Authors developed the concept and design of the ques-
tionnaire. However, certain questions were adapted and/or
incorporated, with approval from lead author and journal
publisher, from a previously published survey completed in
2011 looking at strategies of high-volume German neuro-
surgical departments (not individual surgeons) [19]. Iden-
tical case examples from that survey and representative
figures, were also used (Figs. 2, 3, 4).
Results
A total of 356 emails were sent with 87 (24.7 %) responses
collected over a 3 month period (March–May 2013). Sixty-
five (75 %) responses were from practicing neurosurgeons
while twenty-two (25 %) were from trainees. The majority
of results discussed in the paper are therefore primarily
based on responses from practicing surgeons unless
otherwise stated. Relevant responses from surgeons and
trainees are summarized in Table 1. Sixty-one responses
(94 %) were completed in English and 4 (6 %) were
completed in French. The range of years of practice was
less than 5 years 22 % (n = 14), 5–10 years 14 % (n = 9),
11–15 years 14 % (n = 9), 16–20 years 14 % (n = 9),
21–25 years 14 % (n = 9), and 26 years or greater 23 %
(n = 15). Thirty-one (48 %) stated that they considered
their practice to have a neuro-oncology focus.
Nighty-four percent of surgeons (n = 47) and trainees
(n = 20) believe that we do not know the ‘‘right treatment’’
for any given patient presenting with a presumed newly
diagnosed LGG.
Clinical presentation and diagnostic workup
For a patient presenting solely with a new onset seizure with
a lesion suspicious for a LGG, 26 % (n = 17) considered
this individual to be asymptomatic while 74 % (n = 48)
stated that this patient is symptomatic. When asked the same
question but now with recurrent seizures, 12 % (n = 8)
believed that this patient is asymptomatic while 88 %
(n = 57) stated that this patient is symptomatic. MRI was
considered a ‘‘standard’’ diagnostic workup for a LGG by
100 % (n = 62) of respondents, while MR Spectroscopy
and Positron Emission Tomography (PET) were considered
standard workup in 23 % (n = 14) and 3 % (n = 2),
respectively. The vast majority of surgeons (90 %, n = 56)
do not obtain neurocognitive assessments.
Surgical management
Surgical options for the LGG patient include biopsy
(frameless or frame-based needle biopsy, open surgical
biopsy), and surgical resection. Biopsy alone was deemed
appropriate in various circumstances. When given the
opportunity to select more then one response for when the
surgeon uses a biopsy in the context of LGGs; upfront biopsy
on all first presentations for diagnostic purposes was selected
by 21 % (n = 13). Biopsy for grossly unresectable tumor
(i.e.: eloquent area) was suggested by 39 % (n = 24).
Seventy-five percent (n = 46) of surgeons use a biopsy
when there is demonstrated tumor growth, and for diagnosis
in cases with tumor enhancement on MRI in 79 % (n = 48).
When gross-total resection is possible, responders chose
from the following perceived benefits, with more than one
benefit being allowed in the response : providing a histo-
logical diagnosis (surgeon: 93 %, n = 57; trainee: 91 %,
n = 20), for seizure reduction (surgeon: 74 %, n = 45;
trainee: 41 % n = 9), to increase PFS (surgeon: 75 %,
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How many years of practice? Do you have an Oncology focus?
Do you consider a patient 
with a lesion suspicious for a 
low-grade glioma after a first 
single seizure as 
asymptomatic?
What imaging modalities are 
standard for your workup?
Do you routinely obtain 
neuropsychological or 
neurocognitive assessments ? 
In a clinically stable patient, 
when do you decide to do a 
biopsy for histological diagnosis?
What is the benefit of an open surgery 
when gross-total resection is possible?
In the case of a tumor in a NON-
ELOQUENT area; which 
modalities do you use? 
In the case of a tumor in an 
ELOQUENT area; which 
modalities do you use? 
If you use awake craniotomy, 
how often do you use cortical 
stimulation to guide resection?
Do you routinely check the 
extent of resection with an 
early postoperative MRI 
(within 72 hours)?
In your surgical experience, how often have 
you taken a patient back to the operating room 
(on the same hospital admission) because the 
extent of residual is greater than expected?




Factors Influencing Decision Making
Postoperative Care
Influencing Decision Making 
Patient Related 
Factors Influencing Decision Making
Surgical Related 
Factors Influencing Decision Making 
In a patient with a 2 cm maximum diameter 
residual tumor (non-eloquent area) in the early 
(less than 3 months) postoperative MRI and 
tumor histology of ASTROCYTOMA (Grade II); 
you would ADVOCATE for:
Options:
- Resection of residual 
- Early adjuvant radiotherapy alone 
 - Early adjuvant chemotherapy alone
- Delay Radiation until radiological evidence of 
progressive disease 
- Delay Chemotherapy until radiological evidence of 
progressive disease  
- Delay Radiation/Chemotherapy until radiological 
evidence of progressive disease  
- Follow with serial imaging with the possibility of future 
surgery
Which chemotherapy agent has 
most commonly been prescribed for 
your patients with diffuse low grade 
gliomas?
Does the IDH or 1p19q 
status alter your decision 
for surgical management 
for your patients?
Do you feel we know 
the “right treatment” for 
any given patient 
newly presenting with 
a presumed LGG?
In a patient with a 2 cm maximal diameter 
residual tumor (non-eloquent area) in the 
early (less than 3 months) postoperative MRI 
and tumor histology of 
OLIGODENDROGLIOMA (Grade II); you 
would ADVOCATE for:
Fig. 1 Flow diagram
illustrating questions presented
to practicing neurosurgeons and
trainees in Canada. Survey
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n = 46, trainee: 95 %, n = 21), to increase overall survival
(surgeon 64 %, n = 39, trainee: 68 %, n = 15), to decrease
intracranial pressure (surgeon: 72 %, n = 44; trainee: 55 %,
n = 12) and for cytoreduction before adjuvant therapy
(surgeon: 77 %, n = 47; trainee: 77 %, n = 17). Thirty-six
percent of responders (n = 22) did not believe that gross-
total resection would benefit overall survival.
Responders were asked about the role of intraoperative
surgical adjuncts in a non-eloquent tumor, again with more
than one choice allowed. Navigation was used by all;
intraoperative ultrasound was used by 32 % (n = 19);
awake craniotomy by 13 % (n = 8) and intraoperative
MRI by 10 % (n = 6). For eloquently located tumors,
97 % (n = 58) used navigation, 80 % used awake cran-
iotomy (n = 48), 35 % (n = 21) used neurophysiological
monitoring, 30 % used functional MRI (n = 18), 27 %
(n = 16) used diffusion tensor imaging (tractography), and
8 % (n = 5) used intraoperative MRI.
Fig. 2 How would you treat this patient? A 24 year old right hand dominant female patient with a history of 2 generalized seizures. MRI FLAIR
sequence is shown. There was NO enhancement with gadolinium
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Fifteen surgeons (25 %) did not perform awake cran-
iotomy in their practice. The remainder that did stated that
cortical stimulation was used always 38 % (n = 23), reg-
ularly 32 % (n = 19), seldom 5 % (n = 3) or never 0 %
(n = 0). Subcortical stimulation was used always 7 %,
(n = 4), regularly 18 % (n = 11), seldom 33 % (n = 20)
or never 17 % (n = 10).
Postoperative management
MRI within the 72 h postoperative time window was used
by 72 % (n = 44) of surgeons. The remaining surgeons
obtained imaging within 1 month (n = 2), 3 months
(n = 14), and 6 months (n = 2).
Residual disease
Thirty-four surgeons (57 %) have never required to repeat
surgery during the same hospital admission due to residual
tumor greater than expected, while 37 % (n = 22) reported
having required to repeat surgery during the same admission
in less than five patients in their career. In a patient with a
2 cm maximum diameter residual tumor (non-eloquent
area) in the early (less than 3 months) postoperative MRI
and tumor histology of astrocytoma, 69 % (n = 35) would
delay treatment, 27 % (n = 14) would reoperate, and 4 %
(n = 2) would recommend radiotherapy. When asked the
same question with a pathology showing oligoden-
droglioma, 56 % (n = 28) would delay treatment, 26 %
Fig. 3 How would you treat this patient? A 52 year old male, right hand dominant, presents with simple partial seizures with motorized aphasia.
Neurologically intact. MRI FLAIR sequence is shown. There was NO enhancement with gadolinium
J Neurooncol (2016) 126:137–149 141
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(n = 13) would reoperate, 16 % (n = 8) would recommend
chemotherapy, and 2 % (n = 1) recommend radiotherapy.
Recurrent disease
In an eloquently located LGG after biopsy showing an
astrocytoma in a patient with intractable seizures managed
with two anti-epileptic drugs, 32 % (n = 16) would
advocate for radiation therapy alone, 6 % (n = 3) for
chemotherapy alone, the remaining surgeons would either
delay intervention chemotherapy/radiation until the time of
tumor progression (38 %, n = 19), or suggest a wait-and-
see approach when seizures controlled to intervene (24 %,
n = 12). When asked the same question for biopsy results
showing an oligodendroglioma, 50 % (n = 25) would
advocate for chemotherapy only, 4 % (n = 2) for radio-
therapy only, 22 % (n = 11) would delay radiation/
chemotherapy until tumor progression while 24 %
Fig. 4 How would you treat this patient? A 49 year old male right hand dominant presents with complex-focal seizures, without any
neurological deficit. MRI FLAIR sequence is shown. There was no enhancement with gadolinium
142 J Neurooncol (2016) 126:137–149
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(n = 12) would wait-and-see when seizures controlled to
intervene.
Temozolomide was the most common chemotherapy
prescribed by 92 % of respondents (n = 46), followed by
procarbazine, lomustine, vincristine (PCV) by 6 %
(n = 3).
Multidisciplinary care
Fifty-percent (n = 25) of the surgeons surveyed play an
active role in decision making for the use of adjuvant
treatment (chemotherapy and/or radiation) in their patients
with 78 % (n = 40) stating that they review all of their
LGG in at a multi-disciplinary tumor board.
Molecular genetic analysis
Sixty-eight percent (n = 34) of surgeons state that the
isocitrate dehydrogenase (IDH) or 1p19q status did not
alter their decision for surgical management. When this
response was subdivided into years of practice, senior
surgeons were more likely to rely on these molecular
markers than trainees and younger surgeons (trainee 11 %,
n = 2;\10 years: 26 % n = 5; 11–20 years: 27 % n = 4;
[21 years: 44 % n = 7).
1p19q loss of heterozygosity (LOH) status was the most
routinely determined molecular marker requested (96 %,
n = 47), followed by p53 mutation (45 %, n = 22),
MGMT methylation status (39 %, n = 19), IDH1 mutation
(37 %, n = 18) and finally EGFR mutation (14 %, n = 7).
Cases
Case 1 (Fig. 2) illustrates a LGG in a left superficial frontal
location in a 24 year-old right hand dominant female with a
history of two generalized seizures. Upfront interventions
recommended: biopsy 16 % (n = 8), a ‘‘wait-and-see’’
strategy 23 % (n = 12), awake craniotomy 61 % (n = 31).
When subdivided into years of practice (Table 2) awake
craniotomy was more common in trainees 67 %, (n = 12)
and younger surgeons with 79 % (n = 15) in less than
10 years of practice, 60 % (n = 9) in 11–20 years of
practice, and 41 % (n = 7) in [21 years of practice. A
biopsy was more commonly suggested in older surgeons
(27 % n = 4, 11–20 years; 18 % n = 3,[21 years) when
compared to younger surgeons (5 % n = 1,\10 years) and
trainees (11 %, n = 2). A ‘‘wait-and-see’’ strategy was
more common in senior surgeons (42 % n = 7,[21 years)
than in younger surgeons (16 % n = 3, \10 years; 13 %
n = 2, 11–20 years) and trainees (22 %, n = 4).
Case 2 (Fig. 3) depicts a 52 year-old right hand domi-
nant male, presenting with a history of simple partial sei-
zures with transient expressive aphasia that is
neurologically intact with imaging of a left inferior frontal
Table 1 Select responses of
surgeons (n = 65) and trainees
(n = 22) for management of
LGGs
Surgeon (%) Trainee (%)
Consider first presentation of LGG with seizure as asymptomatic 26 41
Biopsy upon first presentation 21 23
Awake craniotomy alters surgical outcome 75 91
GTR increases progression free survival 75 95
GTR increases overall survival 64 68
Awake craniotomy for eloquent tumor 80 100
Cortical stimulation 93 83
Subcortical stimulation 38 14
Postop MRI\72 h 72 77
IDH or 1p19q alters surgical management 68 89
Do we know the ‘‘right treatment’’? 94—no 94—no
Table 2 Three cases (Fig. 2, 3, 4) of increasing complexities were
presented with multiple options of management shows results of
younger (n = 23; \10 years), middle (n = 18; 11–20 years) and
senior surgeons (n = 24;[20 years of practice)
Case 1 Case 2 Case 3
Awake surgery Trainee 67 % Trainee 39 % Trainee 39 %
Younger 79 % Younger 42 % Younger 16 %
Middle 60 % Middle 27 % Middle 13 %
Senior 41 % Senior 18 % Senior 0 %
Biopsy Trainee 11 % Trainee 44 % Trainee 28 %
Younger 5 % Younger 42 % Younger 74 %
Middle 18 % Middle 73 % Middle 73 %
Senior 27 % Senior 29 % Senior 29 %
‘‘Wait-and-see’’ Trainee 22 % Trainee 17 % Trainee 33 %
Younger 16 % Younger 16 % Younger 26 %
Middle 13 % Middle 0 % Middle 20 %
Senior 42 % Senior 53 % Senior 65 %
Senior surgeons are more inclined to choose a ‘‘wait-and-see’’
approach and less likely to perform awake surgery
J Neurooncol (2016) 126:137–149 143
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LGG (in/near eloquent cortex). Upfront interventions sug-
gested: Biopsy 47 % (n = 24), awake craniotomy 30 %
(n = 15), a ‘‘wait-and-see’’ strategy 23 % (n = 12). When
subdivided into years of practice (Table 2) awake cran-
iotomy was more common in trainees (39 %, n = 7) and
younger surgeons 42 % (n = 8) with less than 10 years of
practice, 27 % (n = 4) in 11–20 years of practice, and
18 % (n = 3) in[21 years of practice. A biopsy was more
commonly suggested in the 11–20 years of practice sur-
geons (73 % n = 11, 11–20 years) followed by young
surgeons (42 % n = 8, \10 years) and trainees (44 %
n = 8) and finally senior surgeons at 29 % (n = 5). A
‘‘wait-and-see’’ strategy was more common in senior sur-
geons (53 % n = 9,[21 years) than in younger surgeons
(16 % n = 3, \10 years; 0 % n = 0, 11–20 years) and
trainees (17 % n = 3).
Case 3 (Fig. 4) describes a 49 year-old right hand
dominant male with complex-focal seizures, without any
neurological deficit, and an MRI demonstrating a left
insular LGG. Upfront interventions suggested: Biopsy
53 % (n = 27), awake craniotomy 10 % % (n = 5), a
‘‘wait-and-see’’ strategy 37 % (n = 19). When subdivided
into years of practice (Table 2) awake craniotomy was not
a common choice among surgeons with 16 % (n = 3) in
\10 years of practice, 13 % (n = 2) in 11–20 years and
0 % (n = 0) in[21 years, but was the most popular with
trainees 39 % (n = 7). A biopsy was less likely chosen in
senior surgeons at 29 % (n = 5) and trainees (28 %,
n = 5) when compared to younger surgeons (\10 years of
practice) 74 % (n = 14) and surgeons with 11–20 years of
practice 73 % (n = 11). A ‘‘wait-and-see’’ strategy was
more common in senior surgeons (65 % n = 11,
[21 years) than in younger surgeons (26 % n = 5,
\10 years; 20 % n = 3, 11–20 years) and trainees 33 %
(n = 6).
In all three cases not one individual decided to radiate or
give chemotherapy prior to any surgical intervention.
Discussion
Diffuse LGG, a WHO grade II glioma, is characterized
with anaplastic transformation over a 10 year period on
average [20–22]. As stated by the European guidelines,
maximal resection is currently the first therapeutic option
in LGGs [23]. American guidelines also recommend
maximal safe surgical resection, however, observation is
appropriate for select patients [24]. The best management
strategy has yet to be defined and remains a topic of great
controversy, with traditional practices supporting a ‘‘wait-
and-see’’ conservative approach while more recent data
supports aggressive upfront resection to delay anaplastic
progression and improved quality of life [25]. Of note is the
recent recognition of molecular subtypes of LGG, includ-
ing IDH mutation and 1p/19q co-deletion, which are of
increasing clinical relevance. No doubt in the future such
markers will be incorporated into practice guidelines as
molecular information becomes integral to tumor
classification.
We chose to investigate the practice patterns of neuro-
surgeons in Canada by surveying a diverse cohort of trai-
nee and practicing neurosurgeons. We were able to collect
an array of information that establishes the current national
practice patterns, ranging from workup, as well as pre-,
intra-, and post-operative management, and inquire about
surgical management in three hypothetical cases ranging in
complexity. This study demonstrates that there is no uni-
form approach to the management of LGGs in Canada. The
information provided by this cohort establishes concepts
concerning (i) the prevalent variability in management of
LGGs nationally, suggesting the importance for introduc-
ing best practice guidelines for this disease (ii) areas of
(re)education to establish a comprehensive and uniform
management strategy of LGGs (iii) provide an opportunity
for directing future studies nationally. Understanding the
existing practice patterns across Canada will help to guide
further initiatives not only nationally but internationally.
Clinical management
Recent advances in neuroimaging have allowed for earlier
diagnosis of gliomas, in patients with minor symptoms,
single seizures or even those who are asymptomatic (in-
cidental discovery) [26]. In this study 26 % of neurosur-
geons surprisingly were unaware that a seizure can be
symptomatic of a LGG. A lack of appreciation of this
important fact could potentially delay intervention with
negative clinical consequences. In addition, several reports
support the effectiveness of surgery at improving seizure
control after resection [27, 28].
Neurocognitive assessment
It is well recognized that a standard neurological exami-
nation is not accurate enough to objectively assess patients
with a LGG [29, 30]. While not yet a standard of care,
neurocognitive assessments allow for a more in-depth
evaluation of subtle deficits that may be present prior to
treatment in LGG patients, and serve as a valuable baseline
with which to compare subsequent clinical changes fol-
lowing treatment or in the setting of disease progression.
This is of importance in part due to the longer life expec-
tancy observed in this population and the impact on quality
of life the disease and ongoing treatment may have, as
compared with the high-grade glioma population. In our
study, 90 % of surgeons reported that they do not routinely
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obtain any neuropsychological or neurocognitive assess-
ments. Importantly, more than 90 % of LGG patients
experience at least some neurocognitive deficit (for
example, working memory disorders) prior to any treat-
ment [29]. In the future, clinical studies, focusing on sys-
tematic neuropsychological examinations directed at
defining valid, reproducible and efficient batteries of neu-
rocognitive testing for LGG patients will be needed.
Intraoperative adjuncts
Our study showed that 50 % of neurosurgeons ‘‘seldom or
never’’ use intraoperative subcortical stimulation to guide
tumor resection. The rate of permanent neurological defi-
cits have been shown to be significantly reduced with
awake mapping with less than 2 % in a recent series using
intraoperative stimulation, in comparison with 15–20 % of
severe worsening in series with no mapping [31–33]. One
possibility for the uncommon use of intraoperative stimu-
lation to guide tumor resection is the unfamiliarity with the
approach as well as interpretation of the proper responses,
especially for subcortical stimulation. Additionally, the
familiarity of anesthesiologists with awake surgery could
also play a role in a surgeon’s choice for surgical approach.
Overall, this result highlights the need to introduce more
dedicated fellowships, and educational courses for both
practicing and in-training surgeons to acquire the skill set
and experience needed to perform awake mapping, with the
most realistically effective strategy being to promote sub-
specialty fellowship training in this area. Furthermore,
dissemination of existing studies and establishing standards
of care by the neuro-oncology community to define the
value of such adjuncts is valuable. An alternative approach
to consider focusing the management of LGGs, at centers
with the necessary subspecialty services, also referred to as
‘‘centers of excellence’’. This approach will only be suc-
cessfully adopted if as a community neuro-oncology rec-
ognizes the value and need for specialized centers
managing LGGs.
Wait-and-see, surgery and extent of resection
A complete discussion of the ‘‘wait-and-see’’ approach
versus surgery and extent of resection is beyond the scope
of this study. In brief, most of the available retrospective
literature suggests a survival benefit from aggressive sur-
gical resection [17, 34–36], although there are data that
reported no difference [37]. Maximal safe resection may
also delay or prevent malignant progression [10, 38, 39]
and recurrence [2].
A ‘‘wait-and-see’’ strategy continues to be common-
place in Canada especially amongst senior neurosurgeons
as observed in the three cases in the survey. A subgroup
analysis revealed that in all three proposed cases, surgeons
with more than 20 years of practice were more likely to
choose a ‘‘wait and see’’ approach (case 1, 42 %; case 2,
53 %; case 3, 65 %) compared to surgeons with less than
10 years of practice (case 1, 16 %; case 2, 16 %; case 3,
26 %). Whether this is a reflection of skepticism in
advantages of surgical resection is unclear, however con-
firms a ‘‘wait-and-see’’ strategy has been the traditional
teaching that is propagated in practice in Canada as we see
from this study. There is no doubt that observation is
desirable when tumors invade areas such-as primary motor
or the paracentral lobule; however, the evidence in favor of
observation is waning for areas of non-eloquence (e.g. right
frontal lobe).
The data on clinical approaches towards surgical man-
agement of LGGs is in evolution, and though level 1 evi-
dence is lacking with respect to the best surgical and
medical approach, there is accumulating literature to sup-
port a role for early surgical intervention and attempt at
near complete resection. However, given lack of definitive
data taken together with the fact that LGGs are relatively
uncommon and the concept of promoting dedicated centers
for treatment of LGG is not yet adopted widely, it is to be
expected that surgeons who have maintained a practice
pattern across a number of years (such as senior surgeons
in this survey), might chose to continue to take a more
conservative approach with a’wait-and-see’ strategy unless
definitive evidence is forthcoming to compel a change in
management. Centralization of management of LGG in
dedicated multidisciplinary settings with necessary sub-
specialty expertise is important in the path to make a cul-
ture and paradigm change a reality.
The argument for a more aggressive surgical approach
has been shown by Berger and others who have found that
both the preoperative as well as the postoperative volume
to be of prognostic significance for the time to progression
[2, 40]. A recent Norwegian study had shown the signifi-
cant difference of survival in those centers with a prefer-
ence for resection than those selecting a biopsy and
watchful waiting [41] and with no significant difference in
health related quality of life [42]. It is possible that the
preference of ‘‘younger’’ surgeons to be more ‘‘aggressive’’
in achieving surgical debulking of a LGG is a sign of
changing tide from ‘‘senior’’ surgeons that towards the goal
of extensive resection to significantly delay, if not avoid,
anaplastic transformation of the glioma.
The rationale for GTR when safely achievable [43] is
that MRI underestimates the actual spatial extent of LGG
invasion even when they appear well-delineated, which
suggests that an extended resection of a margin beyond
MRI-defined abnormalities, might improve outcome. This
can be achieved in some cases by real time feedback by
awake surgery with cortical and subcortical stimulation
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using such tasks as described earlier. However, recent
studies looking specifically at oligodendroglioma show that
extent of resection does improve PFS and overall survival
but did not influence time to malignant transformation [44].
Clearly, more studies from single and multi-centers are
required to further evaluate extent of resection in the var-
ious pathologies of LGGs.
A meta-analysis on the impact of brain mapping on
glioma surgery outcome clearly showed that there were
fewer severe neurological deficits and more extensive
resections in tumors within eloquent regions when brain
mapping was used [45]. In our view, the evidence is
overwhelming that mapping, asleep or awake, during sur-
gery for gliomas in eloquent regions should become the
standard of care. The results of this study show that
younger surgeons are more likely to perform awake sur-
gery, underscoring the importance of including this surgi-
cal approach as a mainstay of residency and fellowship
training. Furthermore, local seminars or courses provided
by leaders in the field should be made available to prac-
ticing surgeons on the technical nuances of awake surgery,
anesthesia, cortical and subcortical mapping, and intraop-
erative tasks.
Adjuvant therapy
Temozolomide was the chemotherapy of choice in 92 % of
respondents. Studies suggest that temozolomide has effi-
cacy in the treatment of recurrent LGG, with response rates
of 25–56 % [46, 47]. A recent study evaluated both quality
of life and neurocognition of patients who were treated
with a combination of chemotherapy and surgical resection
for a LGG, showing an excellent tolerance of combined
therapies [48]. Some have also proposed the use of pre-
operative chemotherapy for recurrent disease to allow for
more extensive surgery [49].
Radiation therapy for LGG has been associated with
impaired cognitive and executive function [50]. Two
seminal randomized trials from the European Organization
for Research and Treatment of Cancer (EORTC) have
provided evidence to guide the postoperative management
of low-grade glioma. Both trials, EORTC 22844 [51] and
22845 [52] showed no benefit of overall survival (OS), but
the latter did show improved PFS and supported the option
of delaying the use of postoperative therapy for a select
group of patients. More recently updated results of RTOG
9802, a phase III trial that randomized higher risk patients
(and observed lower risk patients) with LGG to fraction-
ated radiotherapy plus or minus 6 cycles of postradiation
PCV demonstrate a substantial improvement in overall
survival in the PCV arm (13.3 vs 7.8 years) [53]. High-risk
was defined as patients with diffuse gliomas (regardless of
histology) who were 40 years or older with any extent of
resection and patients who were 18 years or older whose
tumors were less than completely resected. The subset of
patients with LGG most likely to benefit from adjuvant
postoperative radiotherapy has not been defined, and there
is a lack of consensus about which patient- and tumor-
specific factors confer a higher risk of progression. For our
survey not a single surgeon decided to radiate or give
chemotherapy prior to any surgical intervention in the three
hypothetical cases.
When provided with a scenario of a patient with
intractable seizures on two antiepileptic medications with
an eloquent tumor of (i) astrocytoma histology, 62 %
choose to delay any adjuvant therapy (includes delay
radiation, chemotherapy and the ‘‘wait-and-see’’ cohort).
However when the histology was (ii) oligodendroglioma,
50 % recommend upfront chemotherapy, 4 % for upfront
radiation, while 46 % delayed any adjuvant therapy (in-
cludes delay radiation, chemotherapy and the ‘‘wait-and-
see’’ cohort). There are several issues for discussion here.
First we see the preference to observe a LGG rather than
provide adjuvant therapy when surgery is not an option.
Despite the low toxicity of chemotherapy (as described
above) or the ability of radiotherapy to impede growth, the
choice to avoid any intervention seems controversial.
Second, the high preference of surgeons to select
chemotherapy for oligodendroglioma but not astrocytoma
histology was unexpected. This could be related to the
respondents inferring the established sensitivity of
anaplastic oligodendroglioma (WHO grade III) to
chemotherapy [54, 55], however no current guidelines
support the preference of treatment of based upon histology
in LGGs [55].
Recurrence
A large study, done in conjunction with the French Low-
Grade Glioma Consortium, showed that anaplastic trans-
formation can be significantly delayed after a more
aggressive resection, and thus change the natural history of
the disease. The authors also demonstrated that the resec-
tion of recurrent LGG significantly influenced survival in a
multivariate analysis [17, 39].
The fact that LGG are slow-growing lesions allows the
brain time to undergo plasticity in certain areas (i.e. lan-
guage) [56–60]. The role of multistage surgical approaches
makes it possible for a LGG removal in critical regions
traditionally considered as unresectable, such as Broca’s
area, Wernicke’s area, and the insular lobe (even in the
‘‘left dominant’’ hemisphere) [61–63]. This is explained by
our better understanding of the plasticity phenomena and
the functional reshaping (verified by intraoperative awake
mapping) [59]. When asked about re-operation for recur-
rence (max diameter 2 cm), younger surgeons were more
146 J Neurooncol (2016) 126:137–149
123
likely to follow with serial imaging (68 %) than compared
to senior surgeons (31 %). Its unclear if this was based on
the size of the recurrence, or whether younger surgeons
were implementing this phenomenon of plasticity and
intervening at a later time point though the concept of
plasticity in adults remains yet to be established
definitively.
Limitations
This anonymous, online survey offered a wide spectrum of
data from surgeons and trainees of varying areas of interest,
expertise and practice patterns and provided data that
allowed for discussion of timely relevant and controversial
topics. However, there is no doubt that shortcomings exist
for this study. The overall response rate for the survey was
24.7 %, the response from actively practicing neurosur-
geons was 40 % (65 out of 160 actively practicing aca-
demic neurosurgeons). It should be noted that a lower
response rate to this survey reflects the fact that we
approached all neurosurgeons across all subspecialties. We
note that those without a dedicated neuro-oncology prac-
tice were less inclined to respond to a specialty specific
survey on the topic of LGGs. The response rate for neuro-
oncology neurosurgeons is likely to be higher though a
precise number can not be quoted given variability in
definition of a subspecialty neuro-oncology focussed neu-
rosurgeon. Besides sending repeat emails to non-respon-
ders further options need to be explored to improve survey
response rates. Another shortcoming is that some of the
techniques and technologies such as intraoperative MRI,
awake craniotomy intraoperative mapping are not available
at all centers and their unavailability might therefore have
influenced some of the responses.
Conclusion
In lieu of the results of planned and ongoing studies, it may
be useful to outline specific recommendations for the
management of LGG by either meta-analysis or an expert
consensus interpretation of the available literature [64].
The reality is that a surgical treatment has an important role
but will not in itself be curative for these diffusely infil-
trating tumors. Despite mounting evidence that surgical
intervention may influence the natural history of the dis-
ease in LGG patients, the ultimate ‘‘cure’’ will be in the
realm of non-surgical modalities, and may eventually
become tied to the specific molecular subtype of the tumor.
Until that time we need to provide the best possible man-
agement for this devastating disease. Further focus groups
on optimum treatment are needed [65]. Furthermore, our
hope is that the survey results will provide a forum to
engage clinicians involved and interested in treating LGG
to form a nation-wide working-group that can focus on
identifying further areas of investigations.
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